Physician-owned hospitals hoping to benefit from ACA repeal

The Affordable Care Act (ACA) aimed to limit the growth of physician-owned hospitals by barring existing facilities from expanding and forcing any new ones to survive without Medicare or Medicaid reimbursement. With the law’s fate now in the hands of a Republican-controlled Congress and White House, advocates for these hospitals hope those restrictions will disappear.

Previous studies have shown development of those hospitals slowed to a crawl after 2010. As reported by the Washington Examiner, physician-owned hospitals estimate the law prevented 30,000 jobs from being created and $200 million in new tax revenue being generated thanks to planned hospitals or expansions not moving forward.

“On everything the government has said healthcare reform is supposed to be about, we are leading the pack," said R. Blake Curd, MD, CEO of Sioux Falls Specialty Hospital in South Dakota. “I think they are mad we're better at it. ... They should partner with us and learn from us about how good healthcare can be delivered.”

The new administration at CMS has asked for comments from the industry on rolling back some of those restrictions. Other hospital groups, such as the American Hospital Association, are pressing for the restrictions to stay in place, arguing physician-owned facilities will improperly refer patients to facilities in which they have a financial interest, order unnecessary procedures and try to avoid unprofitable patients.

Read the full article at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.